Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study
Open Access
- 21 June 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (12) , e023357
Abstract
Background: There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID‐19. Methods and Results: The French National Healthcare Data System database was used to conduct a matched‐cohort study. For each adult aged ≥40 years receiving statins for the primary prevention of cardiovascular diseases, one nonuser was randomly selected and matched for year of birth, sex, residence area, and comorbidities. The association between statin use and hospitalization for COVID‐19 was examined using conditional Cox proportional hazards models, adjusted for baseline characteristics, comorbidities, and long‐term medications. Its association with in‐hospital death from COVID‐19 was also explored. All participants were followed up from February 15, 2020, to June 15, 2020. The matching procedure generated 2 058 249 adults in the statin group and 2 058 249 in the control group, composed of 46.6% of men with a mean age of 68.7 years. Statin users had a 16% lower risk of hospitalization for COVID‐19 than nonusers (adjusted hazard ratio [HR], 0.84; 95% CI, 0.81–0.88). All types of statins were significantly associated with a lower risk of hospitalization, with the adjusted HR ranging from 0.75 for fluvastatin to 0.89 for atorvastatin. Low‐ and moderate‐intensity statins also showed a lower risk compared with nonusers (HR, 0.78 [95% CI, 0.71–0.86] and HR, 0.84 [95% CI, 0.80–0.89], respectively), whereas high‐intensity statins did not (HR, 1.01; 95% CI, 0.86–1.18). We found similar results with in‐hospital death from COVID‐19. Conclusions: Our findings support that the use of statins for primary prevention is associated with lower risks of hospitalization for COVID‐19 and of in‐hospital death from COVID‐19.Keywords
This publication has 98 references indexed in Scilit:
- Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modificationsBiochemical Pharmacology, 2015
- Treating influenza with statins and other immunomodulatory agentsAntiviral Research, 2013
- Statins for the primary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews, 2013
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational ResearchCommunications in Statistics - Simulation and Computation, 2009
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008
- Overexpression of ACE2 Enhances Plaque Stability in a Rabbit Model of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Age- and gender-related difference of ACE2 expression in rat lungLife Sciences, 2006
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- The statistical power of abnormal-social psychological research: A review.The Journal of Abnormal and Social Psychology, 1962